EUCTR2008-000213-30-DE进行中（未招募）不适用
Extension study to evaluate long-term-safety of IMA901 plus GM-CSF in advanced renal cell carcinoma patients who achieved a decrease in tumor load or stabilization of their disease after participation in the open-label, multicenter IMA901-202 Phase 2 study
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients who have participated in the core study IMA901-202 over the entire scheduled period and were compliant with the protocol
- •2. Patients who achieved a decrease in tumor load or stabilization of their disease after participation in the core study IMA901-202
- •3. Ability to understand the nature of the study and to give written informed consent
- •4. Willingness and ability to comply with the study protocol for the duration of the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Non compliance in the conduct of the IMA901-202 study
- •2. Women or men who decline to practice a medically approved method of contraception
- •3. Pregnancy or breastfeeding
- •4. Any condition which in the judgement of the investigator would place the patient at undue risk
研究者
相似试验
进行中（未招募）
1 期
A STUDY TO EVALUATE LONG TERM SAFETY OF TOCILIZUMAB IN PATIENTS WITH GIANT CELL ARTERITIS WHO HAVE COMPLETED WA28119 CORE STUDY IN FRANCEGiant cell arteritis (GCA)MedDRA version: 19.1Level: LLTClassification code 10018250Term: Giant cell arteritisSystem Organ Class: 100000004866EUCTR2016-002716-41-FRROCHE SAS10
进行中（未招募）
1 期
ong-Term Evaluation of BIIB067EUCTR2016-003225-41-PLBiogen Idec Research Limited183
已完成
不适用
An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults with C9ORF72-Associated Amyotrophic Lateral SclerosisAmyotrophic lateral sclerosisneurodegenerative disease10029317NL-OMON49747Biogen1
进行中（未招募）
1 期
ong-Term Evaluation of BIIB067Amyotrophic Lateral Sclerosis (ALS)MedDRA version: 20.0Level: PTClassification code 10077024Term: Familial amyotrophic lateral sclerosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-003225-41-BEBiogen Idec Research Limited183
进行中（未招募）
1 期
ong-Term Evaluation of BIIB067Amyotrophic Lateral Sclerosis (ALS)MedDRA version: 20.0Level: PTClassification code 10077024Term: Familial amyotrophic lateral sclerosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-003225-41-DEBiogen Idec Research Limited183